DK200201813A

DK200201813A - New modified vaccinia virus Ankara (MVA) comprising in the viral genome an expression cassette comprising the cowpox ATI promoter or its derivative and a coding sequence, useful for the treatment and/or prophylaxis of viral infections

Info

Publication number: DK200201813A
Application number: DK200201813A
Authority: DK
Inventors: Howley Paul; Leyrer Sonja
Original assignee: Bavarian Nordic As
Priority date: 2002-11-25
Filing date: 2002-11-25
Publication date: 2004-05-26

Abstract

A recombinant modified vaccinia virus Ankara (MVA) comprising in the viral genome an expression cassette comprising the cowpox ATI promoter or its derivative and a coding sequence, where the expression of the coding sequence is regulated by the promoter, is new. - Independent claims are included for the following: - (1) a vaccine or pharmaceutical composition comprising the recombinant MVA; - (2) a method for introducing a coding sequence into target ells by infecting the target cells with the recombinant MVA; - (3) a method for producing a peptide, protein and/or virus by infecting a host with the virus cited above; cultivating the infected host cell under suitable conditions; and - (4) isolating and/or enriching the peptide, protein and/or virus produced by the host cell; - (5) a method for affecting, preferably inducing an immunological response in a living animal body including a human by administering the virus or the composition/vaccine to the animal or human to be treated; - (6) a cell containing the virus; and - (7) method for producing a recombinant MVA by inserting an expression cassette into the genome of MVA. - ACTIVITY - Virucide. - No biological data given. - MECHANISM OF ACTION - Vaccine.

Description

Krav: 1. Rekombinant Modificeret Vaccinia Virus Ankara (MVA) som i det virale genom omfatter en ekspressions kassette hvilket igen omfatter ko-koppe ATI promotoren eller en afledt deraf og en kodende sekvens, hvori ekspressionen af den kodende sekvens er reguleret af denne promotor. 2. Rekombinant MVA som ovenover, hvor ATI promotoren har samme sekvens som SEQ ID: No. 1. 3. Rekombinant MVA ifølge krav 1, hvor den afledte af ATI promotoren er udvalgt fra (i) subsekvenser af sekvensen ifølge SEQ ID: No. 1 og (ii) sekvenser der har en eller flere nukleotid substitutioner, deleteringer, og /eller indsættelser i forhold til sekvensen ifølge SEQ ID: No. I eller i forhold til en subsekvens deraf, hvori denne subsekvens og sekvenser respektivt stadig er aktive som promotorer i MVA. 4. Rekombinant MVA ifølge ethver af kravene 1-3, hvor MVA er udvalgt fra stammen MVA-BN deponeret hos European Collection of Cell Cultures (ECACC) under nummer V00083008 eller en afledt deraf og stamme MVA 575 deponeret hos ECACC under nummer V00120707. 5. Rekombinant MVA ifølge ethvert af kravene 1 -4, hvor den kodende sekvens koder for mindst et antigen, antigenisk peptid og/eller et terapeteutisk stof. 6. Rekombinant MVA ifolgc ethvert af kravene 1 til 5 som vaccine eller medikament. 7. Vaccine eller farmaceutisk komposition der omfatter en rekombinant MVA ifølge ethvert af kravene 1-5. 8. Brug af rekombinant MVA ifølge ethvert af kravene 1-5 til udarbejdelse af en vaccine eller et medikament. 9. En celle der indeholde virussen ifølge ethvert af kravene 1-5. 10. Brugen af ko-koppe ATI promotoren eller en afledt deraf som defineret ifølge ethvert af kravene 1-5 til ekspression af kodende sekvenser i MVA.Requirements: 1. Recombinant Modified Vaccinia Virus Ankara (MVA) comprising in the viral genome an expression cassette which in turn comprises the co-cup ATI promoter or a derivative thereof and a coding sequence wherein the expression of the coding sequence is regulated by this promoter. 2. Recombinant VAT as above, wherein the ATI promoter has the same sequence as SEQ ID: No. The recombinant MVA of claim 1, wherein the derivative of the ATI promoter is selected from (i) sub-sequences of the sequence of SEQ ID NO: 1. 1 and (ii) sequences having one or more nucleotide substitutions, deletions, and / or insertions relative to the sequence of SEQ ID NO. In or relative to a sub-sequence thereof, wherein, respectively, this sub-sequence and sequences are still active as promoters in MVA. A recombinant MVA according to any one of claims 1-3, wherein MVA is selected from the strain MVA-BN deposited with European Collection of Cell Cultures (ECACC) under number V00083008 or a derivative thereof and strain MVA 575 deposited with ECACC under number V00120707. The recombinant MVA of any of claims 1-4, wherein the coding sequence encodes at least one antigen, antigenic peptide, and / or a therapeutic agent. 6. Recombinant VAT according to any one of claims 1 to 5 as a vaccine or drug. A vaccine or pharmaceutical composition comprising a recombinant MVA according to any one of claims 1-5. Use of recombinant MVA according to any one of claims 1-5 for the preparation of a vaccine or a medicament. A cell containing the virus according to any one of claims 1-5. The use of the co-cup ATI promoter or a derivative thereof as defined in any one of claims 1-5 for expression of coding sequences in MVA.